||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Indivior Share Discussion Threads
Showing 176 to 197 of 200 messages
|I think the CMA decision to fine Pfizer over the pricing of its anti epilepsy drug had a wash through effect here.Natter about unfair pricing,compromising generic competition etc,all potentially very relevant re anti trust allegations surrounding Suboxone.Time will tell.There's a witch hunt going on.|
|Could well be right! I note the property market has escaped the Trump affect so far. Could I assume that he will pronounce adversely on that at some stage!!|
|From aircraft to refrigeration and drug manufacturers,Mr Trump has a view on all things.I think with litigation in the wings,the price fall today was reactive rather than predictive but that's a guess of course.The drug stocks have lost their mojo in a market that fairly slavishly follows bonds in feeling that US growth and inflation are on the horizon.Many slip between cup and lip.|
|Mm, Volume surprisingly high here. The R and D day is on the 9th December and starts at 7.30 am NY time . Obviously someone somewhere either knows or wants us to believe they know something. We are awaiting a further legal ruling on the various patent cases but this is actually a tad behind the envisaged schedule. Maybe Mr Trump has panicked a holder but I will sit and wait for news. Over the years in many/most stocks its worked for me.|
|Trump's twitters have weakened sentiment towards drug stocks with talk of imposing drug price cuts.He's going to be a busy little bee when he takes office.He makes for a feral equity market with his unencrypted comments.|
|And up go all the drug stocks on the Trump victory.Back in the 1990s ,I went to a Smithkline Beecham meeting.At the front of the hall was a photo of Hilary Clinton."You're probably wondering why we have this photograph here", said a member of the SKB team,"it's here to remind you that this woman is NOT the President of the United States!"The dislike of Hilary Clinton is pretty universal amongst drug companies emanating from all those years ago when she attacked their practises and profitability.Today we're enjoying a relief rally that she's not in power.|
|remembr though that the litigation problem remains - i wont add until this is resolved|
|Thanks for the link. It provides a great read.|
|Steeplejack, only you and I seem to post on this one!
I listened to the conference call on the trading update and one question interested me. An analyst referred to the $220m legal provision and queried whether Reckitt had any potential liability.
Indivior stonewalled as it did on all legal provision questions but the CEO acknowledged, but only when pointed out, that Reckitt had made a reference to the legal situation in its last trading update(19 October although I missed it). I have pasted the extract below. Reckitt appears to be acknowledging that it could have some liability. Obviously some warrenties would have been given at the time of the demerger, as they always are in these situations. Maybe that statement spurred Indivior on to making a provision now!
"Indivior / RB Pharma related matters:
We noted in our 2015 Annual Report and 2016 interim announcement that the Group was involved in ongoing investigations by the US Department of Justice and the US Federal Trade Commission and related litigation proceedings in relation to certain matters relating to the RB Pharmaceuticals business prior to its demerger in December 2014 to form Indivior PLC and may incur liabilities in relation to such matters. These investigations and related proceedings are continuing and the outcome for the Group at this stage remains uncertain. The Company continues to work to ensure that these investigations and related proceedings are concluded or resolved satisfactorily."|
|Mm, so the market likes the 3rd qtr.
The upgraded revenue forecasts for the year are encouraging as is the gradual development of the product pipeline. Could be great excitement down the line from these new products! Yet the litigation situation is to me so complex I just cannot get my head around it. It might be the $220m provision is the first quantification of downside possibilities and investors are reassured but at this stage that scenario seems too simplistic.
No doubt will learn more in time.|
|Article seems to suggest the generic plaintiffs believe INDV shouldn't have tried to find alternative delivery methods, which can be patent protected and where there are no generics. Hardly the attitude of the land of the free.
However I am concerned about the effect of the suit in the medium term, considering the behaviour of Illumina against NIPT and the effect on its share price|
|Looking at the situation and without huge knowledge, the 35 States appear to be attempting to turn a corporate competive advantage into something else. Can see why the Company is vigorously defending its position.|
|From Interim statement In August 2015, the Company was informed that a contingent of additional states has initiated a coordinated investigation into the same conduct that is the subject of the FTC investigation and the Class Action litigation. The existing investigation of these same issues by the State of New York has now been incorporated within this multi-state investigation. On July 1, 2016, Indivior Inc. was notified that 22 states and the District of Columbia intend to file a complaint in the Eastern District of Pennsylvania alleging violations of state and federal antitrust and consumer protection laws relating to the same conduct. The notice indicated that additional states may decide to join in any action and more recently the Company has learned that additional states do intend to join. -- Fact discovery is underway in the Class Action litigation. -- Amneal Pharmaceuticals LLC, a manufacturer of generic buprenorphine / naloxone tablets, has joined the litigation as an additional plaintiff. Amneal's complaint contains antitrust allegations similar in nature to those set out in the class action complaints, and Amneal has also alleged violations of the Lanham Act.Department of Justice Investigation|
|we were warned of this back in JULY ,the time of the interims|
|Big rise followed by big fall?|
|A replacement non executive director as was announced on 7th April. It does again highlight the board wants to bolster its US emphasis in line with the recent ADR. Presume this lady's appointment and background is also designed to add institutional credibility in the USA.|
|does anybody know about the prospect of further litigation-
"Cantor Fitzgerald highlighted the “fast-growing unmet need” for opioid dependency treatment, and securing the longevity of Indivior’s opioid addiction franchise is a primary concern for the broker.
Analysts point out that Indivior is largely dependent on sales of its Suboxone film.
It has had to defend its intellectual property position recently in litigation with Par and Actavis. It has so far been successful. But a settlement has yet to be reached with generic protagonists.
“The recent past has borne witness to a de-risking of the Indivior investment case we believe with the company prevailing in its recent patent. We are still hopeful that a settlement with all of the generic challengers will be the ultimate outcome to remove further uncertainty,” said Cantor."|
|Yes , just finished the telephone conference call and am happy with what was said. Longer term holders will be very happy but haven't a clue re the others!. Steeplejack , Jamie popped up again at the end of the Q and A. Rather pleased and positive is all I need to say!
Indv didn't really answer the earlier cannibalization question which is barely surprising at this early stage. Potential range of envisaged revenues for this product moved up to very top end yet was put in such a way as to sound still conservative. Also, there were some interesting few comments on pre FDA progress of RB7000. Re the detailed questions on the Bup Monthly Phase 3 Trials themselves? A lot of detailed analysis yet to be gone into--all somewhat beyond my pay grade!|
|"Yes,I feel much happier having listened to Jamie conversing with the management.Looks like there's no generic film competitor immediately in the wings and a year out you'll have the once a month injectable,a potentially superior product.So,I'll stick with it."That's what I commented after the question and answer session in early May when Greg recommended listening to analyst "Jamie" from the US Investment house at the end of the meeting.She must be feeling well chuffed given her optimism on that occasion.It looks like they'll be a seamless transfer from an ageing product to this newer potential blockbuster.The management must be over the moon.This is has been a roller coaster ride for shareholders.Hey ho,no gain without pain I guess.|
|Hope people should realise, blockbuster drugs are $1bn per year revenue.|
|Took some now for a quick smash and grab.
My core will be sold till adr and yankees puffing this into orbit. They love good pharmas across the pond|
|Having a really fantastic time here.
MY iog spiked could not topsliced in the spike :(, and to settle for less|